← All countries · Africa
80%
MCV1
2025 · WHO/UNICEF estimate
88%
DTP3
2025 · WHO/UNICEF estimate
9%
IPV complete
2025 · WHO/UNICEF estimate
88%
HepB3
2025 · WHO/UNICEF estimate
751
Measles cases
2025 reported
2
Pertussis (whooping cough) cases
2024 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 88%2025 · WHO/UNICEF estimate | 79.2% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 91%2025 · WHO/UNICEF estimate | 82.4% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 88%2025 · WHO/UNICEF estimate | 79.9% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 86%2025 · WHO/UNICEF estimate | 77.5% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 9%2025 · WHO/UNICEF estimate | 53.8% | too few points | D · poor |
| MCV1First dose of measles-containing vaccine | 80%2025 · WHO/UNICEF estimate | 79.8% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 81%2025 · WHO/UNICEF estimate | 66.7% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 80%2025 · WHO/UNICEF estimate | 79.8% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 88%2025 · WHO/UNICEF estimate | 79.9% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 0%2011 · Administrative (country-reported) | 0% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 88%2025 · WHO/UNICEF estimate | 79.9% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 82.1%2025 · Administrative (country-reported) | 82.1% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 87%2025 · WHO/UNICEF estimate | 79.6% | A · strong | |
| RotaCRotavirus vaccine, complete series | 79%2025 · WHO/UNICEF estimate | 71.3% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | 3%2025 · WHO/UNICEF estimate | 45.9% | C · weak | |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | 0%2011 · Administrative (country-reported) | 0% | D · poor | |
| TCVTyphoid conjugate vaccine | 65%2025 · Administrative (country-reported) | 65% | too few points | D · poor |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 85%2024 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 69%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 69%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 7512025 | 13.1per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 252025 | 0.4per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02012 | 0per 10,000 live births | no data | |
| Mumps all countries · vaccine evidence | 44,3522025 | 770.9per 1,000,000 total population | C · weak | |
| Pertussis (whooping cough) all countries · vaccine evidence | 22024 | 0per 1,000,000 total population | C · weak | |
| Diphtheria all countries · vaccine evidence | 272024 | 0.5per 1,000,000 total population | D · poor | |
| Tetanus (total) all countries · vaccine evidence | 3,9922025 | 69.4per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 892025 | 0.1per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 82023 | 0.4per 1,000,000 <15 population | C · weak | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Japanese encephalitis all countries · vaccine evidence | 02012 | 0per 1,000,000 total population | no data | |
| Invasive meningococcal disease all countries · vaccine evidence | 02023 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 47,1912025 | 820.2per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (40 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | Surviving infants (both male and female) meeting the age of administration |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Other groups | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | W6 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | W10 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | W14 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y10 | HPV for females only | Females meeting the age of administration |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | +M6 | HPV for females only | Females meeting the age of administration |
| IPVIPV (Inactivated polio vaccine) | 1 | W14 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| IPVIPV (Inactivated polio vaccine) | 2 | M9 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| MALARIAMalaria vaccine | 1 | M6 | General/routine · SUBNATIONAL | Offered in 8 counties with prevalence of malaria- Kisumu, Homabay, Siaya, Migori, Vihiga, Kakamega, Busia, Bungoma to the Surviving infants, (both male and female) meeting the age of administration |
| MALARIAMalaria vaccine | 2 | M7 | General/routine · SUBNATIONAL | Offered in 8 counties with prevalence of malaria- Kisumu, Homabay, Siaya, Migori, Vihiga, Kakamega, Busia, Bungoma to the Surviving infants, (both male and female) meeting the age of administration |
| MALARIAMalaria vaccine | 3 | M9 | General/routine · SUBNATIONAL | Offered in 8 counties with prevalence of malaria- Kisumu, Homabay, Siaya, Migori, Vihiga, Kakamega, Busia, Bungoma to the Surviving infants, (both male and female) meeting the age of administration |
| MALARIAMalaria vaccine | 4 | M24 | General/routine · SUBNATIONAL | Offered in 8 counties with prevalence of malaria- Kisumu, Homabay, Siaya, Migori, Vihiga, Kakamega, Busia, Bungoma to the Surviving infants, (both male and female) meeting the age of administration |
| MRMR (Measles and rubella) vaccine | 1 | M9 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| MRMR (Measles and rubella) vaccine | 2 | M18 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| OPVOPV (Oral polio vaccine) | 1 | B | General/routine | Surviving infants (both male and female) meeting the age of administration |
| OPVOPV (Oral polio vaccine) | 2 | W6 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| OPVOPV (Oral polio vaccine) | 3 | W10 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| OPVOPV (Oral polio vaccine) | 4 | W14 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | W6 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | W10 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | W14 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | W6 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | W10 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 3 | W14 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | Pregnant women |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Pregnant women | Pregnant women |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Pregnant women | Pregnant women |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Pregnant women | Pregnant women |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Pregnant women | Pregnant women |
| TYPHOID_CONJTyphoid conjugate vaccine | 1 | M9 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| VITAMINAVitamin A supplements | 1 | M6 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| VITAMINAVitamin A supplements | 2 | M12 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| VITAMINAVitamin A supplements | 3 | M18 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| VITAMINAVitamin A supplements | 4 | M24 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| VITAMINAVitamin A supplements | 5 | M30 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| VITAMINAVitamin A supplements | 6 | M36 | General/routine | Surviving infants (both male and female) meeting the age of administration |
| YFYF (Yellow fever) vaccine | 1 | M9 | General/routine · SUBNATIONAL | Offered in 4 eligible counties-Turkana, Elgeyo Marakwet, Baringo and West Pokot to the Surviving infants, (both male and female) meeting the age of administration |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.